Dr. Reddy's Laboratories Limited (RDY) Earnings History
Elite Compounder26 years of earnings data (2001–2026) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
Dr. Reddy's Laboratories Limited (RDY) Earnings Overview
As of June 30, 2026, Dr. Reddy's Laboratories Limited (RDY) reported trailing twelve-month net income of $42.88B, reflecting -20.4% year-over-year growth. The company earned $51.37 per diluted share over the past four quarters, with a net profit margin of 12.8%.
Looking at the long-term picture, RDY's 5-year EPS compound annual growth rate (CAGR) stands at +21.1%, indicating exceptional earnings growth. The company achieved its highest annual net income of $56.54B in fiscal 2025.
Dr. Reddy's Laboratories Limited maintains positive profitability with a gross margin of 52.8%, operating margin of 13.8%, and net margin of 12.8%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including SUN ($835M net income, 2.1% margin), PRGO (-$1.82B net income, -33.5% margin), AMRX ($122M net income, 2.4% margin), RDY has outperformed on profitability metrics. Compare RDY vs SUN →
RDY Earnings vs Peers
Earnings metrics vs comparable public companies
RDY Historical Earnings Data (2001–2026)
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | $45.09B | -20.3% | $48.87B | $53.92 | 12.8% | 13.8% |
| 2025 | $56.54B | +1.5% | $71.84B | $67.77 | 17.4% | 22.1% |
| 2024 | $55.68B | +23.6% | $67.73B | $66.80 | 19.9% | 24.3% |
| 2023 | $45.07B | +91.2% | $57.14B | $54.17 | 18.3% | 23.2% |
| 2022 | $23.57B | +10049.5% | $29.48B | $28.34 | 11.0% | 13.7% |
| 2021 | $232M | -98.8% | $431M | $20.73 | 9.1% | 16.9% |
| 2020 | $19.50B | +3.7% | $15.99B | $117.40 | 11.2% | 9.2% |
| 2019 | $18.80B | +91.7% | $20.89B | $113.09 | 12.2% | 13.6% |
| 2018 | $9.81B | -18.5% | $11.92B | $59.01 | 6.9% | 8.4% |
| 2017 | $12.04B | -39.8% | $13.50B | $72.09 | 8.5% | 9.6% |
| 2016 | $20.01B | -9.8% | $29.62B | $116.98 | 12.9% | 19.1% |
| 2015 | $22.18B | +3.1% | $26.29B | $129.75 | 15.0% | 17.7% |
| 2014 | $21.51B | +28.2% | $26.03B | $126.04 | 16.3% | 19.7% |
| 2013 | $16.78B | +17.6% | $21.11B | $98.44 | 14.4% | 18.2% |
| 2012 | $14.26B | +29.2% | $18.25B | $83.81 | 14.7% | 18.9% |
| 2011 | $11.04B | +933.7% | $12.63B | $64.95 | 14.8% | 16.9% |
| 2010 | $1.07B | +120.7% | $2.01B | $6.30 | 1.5% | 2.9% |
| 2009 | -$5.17B | -210.5% | -$2.83B | $-30.70 | -7.4% | -4.1% |
| 2008 | $4.68B | -50.0% | $3.36B | $22.80 | 9.4% | 6.7% |
| 2007 | $9.35B | +472.5% | $11.25B | $58.21 | 14.3% | 17.2% |
| 2006 | $1.63B | +673.0% | $1.45B | $10.62 | 6.7% | 5.9% |
| 2005 | $211M | -91.5% | -$366M | $1.38 | 1.1% | -1.9% |
| 2004 | $2.48B | -29.6% | $2.08B | $15.78 | 12.3% | 10.4% |
| 2003 | $3.52B | -28.3% | $3.34B | $23.05 | 19.5% | 18.5% |
| 2002 | $4.92B | +564.9% | $5.06B | $32.27 | 29.6% | 30.5% |
| 2001 | $739M | - | $1.49B | $5.85 | 6.8% | 13.6% |
Download Data
Export RDY earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RDY — Frequently Asked Questions
Quick answers to the most common questions about buying RDY stock.
What is RDY earnings per share (EPS)?
RDY trailing twelve-month (TTM) diluted EPS is $51.37, reflecting -20.4% year-over-year growth. The 5-year EPS CAGR is +21.1%. Complete EPS history from 2001 to 2026 is available in the table on this page.
What is Dr. Reddy's Laboratories Limited's net income?
Dr. Reddy's Laboratories Limited (RDY) trailing twelve-month net income is $42.9B as of 2026. Earnings declined -20.4% year-over-year. Dr. Reddy's Laboratories Limited has been profitable for 17 consecutive years.
Is RDY profitable?
Yes, RDY is profitable with a TTM net income of $42.9B and a net profit margin of +12.8%. Dr. Reddy's Laboratories Limited has generated profits for 17 consecutive years.
What is RDY's earnings growth rate?
RDY compound annual EPS growth rates (CAGR): 1-Year: -20.4%, 3-Year: -0.2%, 5-Year: +21.1%, 10-Year: -7.5%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2001 to 2026.
What are RDY's profit margins?
Dr. Reddy's Laboratories Limited net profit margin is +12.8%, operating margin is +13.8%, and gross margin is +52.8%. Margins are within a typical range for the sector. Return on Equity is +12.7%.
Is RDY growing earnings?
RDY earnings are declining — EPS fell -20.4% year-over-year. TTM net income dropped to $42.9B. This contrasts with the 5-year CAGR of +21.1%.
What was RDY's best earnings year?
Dr. Reddy's Laboratories Limited's highest annual net income on record is $56.5B, achieved in fiscal year 2025. Earnings history on this page spans 2001 to 2026 and includes all annual and quarterly figures.
What were RDY's earnings last quarter?
RDY's most recent reported quarter was Q4 2026. Net income was $2.2B with diluted EPS of $2.68. For a full breakdown of all quarters, see the quarterly earnings table on this page.